Pancreatic cancer in the United States is known for its particularly poor survivability compared to many other cancers. The overall five-year survival rate for pancreatic cancer is approximately **13%**, which is among the lowest survival rates for any cancer type.…
The survivability of breast cancer in the United States has improved significantly over recent decades, reflecting advances in early detection, treatment, and awareness. Breast cancer is the most common cancer among U.S. women, with about one in eight women diagnosed…
The **survivability of lung cancer in the United States** varies significantly depending on the stage at diagnosis, type of lung cancer, and advances in treatment, but overall remains challenging. The general 5-year survival rate for lung cancer is approximately **27%**,…
Caregiver studies play a crucial role in improving research outcomes for non-Hodgkin’s lymphoma (NHL) by providing insights into the lived experiences, challenges, and needs of those who support patients throughout their illness. These studies help researchers and healthcare providers understand…
Chemotherapy-related cognitive decline, often called “chemo brain,” is a significant concern for patients with non-Hodgkin’s lymphoma (NHL). It manifests as problems with memory, attention, processing speed, and executive function, which can severely affect quality of life. Novel therapies are being…
Researchers study the quality of life (QoL) in patients who have both non-Hodgkin’s lymphoma (NHL) and dementia by using a combination of clinical assessments, patient-reported outcomes, caregiver reports, and specialized measurement tools tailored to capture the complex interplay of symptoms…
Research into brain health holds significant promise for improving survivorship in patients with non-Hodgkin’s lymphoma (NHL), particularly those affected by central nervous system (CNS) involvement such as primary CNS lymphoma (PCNSL). This is because NHL that affects the brain or…
Dementia research plays a crucial and multifaceted role in older populations with non-Hodgkin’s lymphoma (NHL), addressing both the direct and indirect cognitive challenges faced by these patients. As the population ages, the intersection of cancer, particularly NHL, and cognitive decline…
Neuroprotective strategies hold significant promise for helping survivors of non-Hodgkin’s lymphoma (NHL) by addressing the neurological complications that often arise from both the disease itself and its treatments. NHL survivors frequently face cognitive impairments, peripheral neuropathy, and other neurophysiological dysfunctions…
Non-Hodgkin’s lymphoma (NHL) research tracks secondary cancer risks through a combination of long-term patient monitoring, detailed data collection, and advanced analytical methods designed to understand how and why survivors might develop new cancers after their initial diagnosis and treatment. This…